Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Leukemia

Free Subscription 20.11.2023 2 Acta Haematol 2 Am J Hematol 4 Ann Hematol 1 Blood 2 BMC Cancer 1 Bone Marrow Transplant 8 Br J Haematol 1 J Natl Cancer Inst

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Haematol

1. RIOS-OLAIS FA, Gil-Lopez F, Mora-Canas A, Demichelis-Gomez R, et al
   Tumor lysis syndrome is associated with worse outcomes in adult patients with acute lymphoblastic leukemia.
   Acta Haematol. 2023 Nov 14. doi: 10.1159/000534453.
   PubMed         Abstract available
   
   
2. ITO K, Harada K, Uchino Y, Hirano K, et al
   A Rare Clinical Case of Secondary Central Nervous System Involvement without Transformation in Hairy Cell Leukemia: Case Report and Literature Review.
   Acta Haematol. 2023 Nov 10. doi: 10.1159/000535066.
   PubMed         Abstract available
   
   

   
   Am J Hematol

3. JOSHI SK, Pittsenbarger J, Kennedy VE, Peretz CAC, et al
   The FLT3(N701K) mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.
   Am J Hematol. 2023;98:E364-E368.
   PubMed        
   
   
4. OLIVA-ARIZA G, Fuentes-Herrero B, Lecrevisse Q, Carbonell C, et al
   Immune cell kinetics and antibody response in COVID-19 patients with low-count monoclonal B-cell lymphocytosis.
   Am J Hematol. 2023;98:1909-1922.
   PubMed         Abstract available
   
   

   
   Ann Hematol

5. ANDERSEN M JR, Bindal P, Michaels P, Elavalakanar P, et al
   Clonal myeloid disorders following CAR T-cell therapy.
   Ann Hematol. 2023;102:3643-3645.
   PubMed        
   
   
6. CHEN B, Zhao Y, Xu S, Jiang F, et al
   USF2 promotes autophagy and proliferation in chronic lymphocytic leukemia by inhibiting STUB1-induced NFAT5 ubiquitination.
   Ann Hematol. 2023 Nov 10. doi: 10.1007/s00277-023-05522.
   PubMed         Abstract available
   
   
7. ZHENG X, Gao H, Lu N, Wang M, et al
   Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms.
   Ann Hematol. 2023;102:3603-3611.
   PubMed         Abstract available
   
   
8. HU J, Zhao J, Wang C, Jia M, et al
   Epstein-Barr virus reactivation correlates with worse outcomes for patients exposed to hepatitis B virus after haploidentical hematopoietic stem cell transplantation.
   Ann Hematol. 2023;102:3593-3601.
   PubMed         Abstract available
   
   

   
   Blood

9. VYAS P
   Changing treatment changing prognosis of mutations.
   Blood. 2023;142:1583-1585.
   PubMed        
   
   

   
   BMC Cancer

10. ZHAO Y, Amorrortu RP, Stewart SC, Ghia KM, et al
    Melanoma and CLL co-occurrence and survival: role of KC history.
    BMC Cancer. 2023;23:1084.
    PubMed         Abstract available
    
    
11. AHMADVAND M, Barough MS, Barkhordar M, Faridfar A, et al
    Phase I non-randomized clinical trial of allogeneic natural killer cells infusion in acute myeloid leukemia patients.
    BMC Cancer. 2023;23:1090.
    PubMed         Abstract available
    
    

    
    Bone Marrow Transplant

12. CAO LQ, Huo WX, Zhang XH, Xu LP, et al
    Peripheral blood stem cell transplantation from haploidentical related donor could achieve satisfactory clinical outcomes for intermediate- or high-risk adult acute myeloid leukemia patients.
    Bone Marrow Transplant. 2023 Nov 15. doi: 10.1038/s41409-023-02117.
    PubMed         Abstract available
    
    

    
    Br J Haematol

13. NG JY, Joshi M, Choi P
    Frequency and outcomes of obinutuzumab-induced thrombocytopenia.
    Br J Haematol. 2023;203:668-672.
    PubMed         Abstract available
    
    
14. BORLENGHI E, Roccaro AM, Cattaneo C
    Rethinking the definition of 'less intensive' for venetoclax-combining regimens in acute myeloid leukaemia patients.
    Br J Haematol. 2023;203:504-506.
    PubMed         Abstract available
    
    
15. REYNOLDS G, Urbancic KF, Fong CY, Trubiano JA, et al
    Invasive fungal infection following venetoclax and posaconazole co-administration.
    Br J Haematol. 2023;203:593-598.
    PubMed         Abstract available
    
    
16. OCADLIKOVA D, Lussana F, Fracchiolla N, Bonifacio M, et al
    Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study.
    Br J Haematol. 2023;203:637-650.
    PubMed         Abstract available
    
    
17. BOOTH E, Backx M, Joshi A, Nizami H, et al
    Disseminated invasive aspergillosis in a patient treated with ibrutinib for chronic lymphocytic leukaemia.
    Br J Haematol. 2023;203:499-500.
    PubMed        
    
    
18. DONNETTE M, Hamimed M, Ciccolini J, Sicard G, et al
    Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients.
    Br J Haematol. 2023;203:625-636.
    PubMed         Abstract available
    
    
19. MONTALBAN-BRAVO G, Kanagal-Shamanna R, Li Z, Hammond D, et al
    Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.
    Br J Haematol. 2023;203:581-592.
    PubMed         Abstract available
    
    
20. APOLITO V, Arrigo G, Vasseur L, Olivi M, et al
    Validation of SIE/SIES/GITMO consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax.
    Br J Haematol. 2023;203:e98-e101.
    PubMed        
    
    

    
    J Natl Cancer Inst

21. SIEGEL DA, King JB, Lupo PJ, Durbin EB, et al
    Counts, incidence rates, and trends of pediatric cancer in the United States, 2003-2019.
    J Natl Cancer Inst. 2023;115:1337-1354.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.